The aim of this work was to confirm our preliminary clinical and immunological evaluation of the protective effects of a herpes simplex virus (HSV) vaccine derived from killed virus in the treatment of relapsing facial or genital herpes simplex infection. A total of 142 patients were treated with the HSV vaccine and a control group of 50 were treated with intermittent oral acyclovir (ACV). The vaccine reduced annual active disease days in vaccinees to 11.59 (±15.3) after treatment (65.11±31.64 before treatment) compared to 30.4±17.49 days after treatment of the control group patients (71.86±32.5 before treatment).
MelnickJLAdamERawlsW.The causative role of herpes virus type 2 in cervical cancer. Cancer1974;34:1355–85.
6.
PaavonenJKoutskyLAKiviatN.Cervical neoplasia and other STD-related genital and anal neoplasias. In: HolmesKKMardhP-ASparlingPF, eds. Sexually Transmitted Diseases, USA: McGraw-Hill, 1990:561–92.
7.
BrokerMAbelKJKohlerRHilfenhausJAmannE.Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protects mice against lethal challenge with HSV-1 and HSV-2. Med Microbiol Immunol Rev1990;179(3):145–59.
8.
ManservigiRGrossiMPGualandriRProtection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells and in a BK virus episomal vector. J Virol1990;64(1):431–6.
9.
ManservigiRIncorvaiaCDe LucaDExperimental keratitis in rabbits by human HSV 1 variants: Prevention and treatment. J Med Virol1990;32(3):148–54.
10.
AltmeyerPWehrenbergOHolzmannHTreatment of recurrent herpes labialis using a herpes simplex type 1 subunit vaccine. A prospective randomized double-blind multicenter study. Hautarzt1991;42(12):759–63.
11.
BurkeRL.Development of a herpes simplex virus subunit vaccine for prophylactic and therapeutic use. Rev Infect Dis1991;13(Suppl 11):S906–11.
12.
GhiasiHNesburnABKaiwarRWechslerSL.Immuno-selection of recombinant baculo-viruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D. Arch Virol1991;121(1–4):163–78.
13.
IshizakaSTMishkinEM.Native HSV glycoprotein D subunit vaccine analysis of in vitro T-cell activation and antigen presentation. Viral Immunol1991;4(3):187–93.
14.
MishkinEMFaheyJRKinoYNative herpes simplex virus glycoprotein D vaccine: Immunogenicity and protection in animal models. Vaccine1991;9(3):147–53.
15.
SkinnerGRB.Chemotherapeutic and immunotherapeutic management of herpes genitalis. Current Obstet Gynaecol1993;3:225–31.
16.
ChanWLLukigMLLiewFY.Helper T-cells induced by an immuno purified herpes simplex virus type 1 (HSV 1) 115 kilodalton glycoprotein (gB) protect mice against HSV 1 infection. J Exp Med1985;162:1304–18.
17.
RosenthalKLSmileyJRSouthSJohnsonDC.Cells expressing herpes simplex virus glycoprotein gC but not gB, gD or gE are recognized by murine virus specific cytotoxic T lymphocytes. J Virol1987;61:2438.
18.
HendricksRLTaoMSPGloriosoJC.Alterations in the antigenic structure of two major HSV-1 glycoproteins, gC and gB, influence immune regulation and susceptibility to murine herpes keratitis. J Immunol1989;142:263.
19.
MartinSCantinERouseBT.Evaluation of antiviral immunity using vaccine virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins. J Gen Virol1989;70:1359.
20.
McBrideBWRidgewayPPhilipottsRJNewellDG.Systemic and mucosal cell-mediated immune responses against herpes simplex virus in vaccinated guinea pigs detected by lymphocyte proliferation and monoclonal antibodies against macrophages and T-cells. Vaccine1989;7:409.
21.
ErtuikMPhillpottsRJWelchMJJenningsR.Efficacy of HSV-1 ISCOM vaccine in the guinea pig model of HSV-2 infection. Vaccine1991;9:728–34.
22.
NasemannTHWaissilewSW.Vaccination for herpes simplex genitalis. Br J Vener Dis1979;55:121–2.
23.
CappelRSprecherSDeCuyperFDeBraekeleerJ.Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol1985;16:137–45.
24.
SkinnerGRBWoodmanCBJHartleyCEThe preparation and immunogenicity of vaccine Ac.NFU1(S-) MRC towards prevention of herpes genitalis in human subjects. Br J Vener Dis1982;58:381–6.
25.
DundarovSAndonovPBakalovBPeevaZ.Immunotherapy with inactivated polyvalent herpes vaccines. Dev Biol Stand1982;52:351–8.
26.
MuniuEMDurhamJShariffDAntibody reactivity in 15 subjects following immunization with Skinner HSV vaccine. Med Microbiol Immunol1987;176:315–27.
27.
TiradrittiLMastrolorenzoAZuccatiGPanconesiE.Studio preliminare dell' effetto clinico ed immunologico di un vaccino antierpetico in un gruppo di soggetti affetti da herpes simplex faciale e genitale recidivante. Int J Drug Ther1988;3:195–205.
28.
KutinovaLBendaRKalosZPlacebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine1988;6:223–8.
29.
MertzGJHashleyRBurkeRLDouble-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis1990;161:653–60.
30.
SkinnerGRBFinkCMellingTReport of 12 years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol1992;180:305–20.
31.
MorteM DellaColucciG.Impiego di metodiche di ibridizzazione e di amplificazione genica nella caratterizzazione di un nuovo antierpetico a base di HSV inattivato contenente le glicoproteine gB e gD. Acta Toxicologica et Terapeutica1992;XIII:1.
32.
MertzGJCoobsRWAshleyRTransmission of genital herpes in couples with one symptomatic and one asymptomatic partner: A prospective study. J Infect Dis1988;157:1169.
BermanPWVogtPEGregoryTLaskyLAKernER.Efficacy of recombinant glycoprotein B subunit vaccine on the development of primary, recurrent and latent genital infections with herpes simplex virus type 2 in guinea pigs. J Infect Dis1988;157:897.
WitmerLARosenthalKLGrahamFLCytotoxic T lymphocytes specific for herpes simplex (HSV) studied using adenovirus vectors expressing HSV glycoproteins. J Gen Virol1990;71:387–96.
NashAALeungKNWildyP.The T-cell mediated immune response of mice to herpes simplex virus. In: RoizmanBLopezC, eds: The Herpes Viruses. Vol IV. New York: Plenum Press, 1985:87–102.
